MEDNAX (MD) Misses Q4 EPS by 31c, Revenues Miss

MEDNAX (NYSE: MD) reported Q4 EPS of $0.05, $0.31 worse than the analyst estimate of $0.36. Revenue for the quarter came in at $417 million versus the consensus estimate of $459.54 million.

For the 2020 fourth quarter, Mednax reported the following results from continuing operations:

• Net revenue of $417 million;
• Earnings from continuing operations of $0.05;
• Income from continuing operations of $4 million;
• Net loss of $64 million; and
• Adjusted EBITDA of $58 million.

“The fourth quarter of 2020 completed a year of significant change, following which we are entirely focused on our Pediatrix and Obstetrix medical group,” said Mark S. Ordan, Chief Executive Officer of Mednax. “While our results continued to be impacted by the COVID-19 pandemic, they also show our enhanced efficiency and financial strength, and we remain confident in the post-COVID earnings power of our organization. We believe we are well positioned to support our affiliated practices, to attract new clinicians and physician groups to Mednax, to grow in other women’s and children’s subspecialties, and to drive strong bottom line results.”

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Shoals ships PowerHub units for 1.1 GW U.S. battery project
• The free USDA tool that tracks egg prices at $0.62/dozen before your data vendor does